↓ Skip to main content

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

Overview of attention for article published in BMC Veterinary Research, August 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)

Mentioned by

twitter
8 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
Published in
BMC Veterinary Research, August 2018
DOI 10.1186/s12917-018-1587-9
Pubmed ID
Authors

Abbey R. Sadowski, Heather L. Gardner, Antonella Borgatti, Heather Wilson, David M. Vail, Joshua Lachowicz, Christina Manley, Avenelle Turner, Mary K. Klein, Angharad Waite, Alexandra Sahora, Cheryl A. London

Abstract

Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study. The objective of this phase II study was to expand upon the initial findings and assess the activity and safety in a larger population of dogs with lymphoma. Fifty-eight dogs with naïve or progressive B-cell and T-cell lymphoma were enrolled in this clinical trial. KPT-335 was administered orally in one of three dosing groups, based on the previously established biologically active dose of 1.5 mg/kg three times weekly. Treatment with single-agent, orally administered KPT-335 resulted in an objective response rate (ORR) of 37%, of which dogs with T-cell lymphoma had an ORR of 71%. KPT-335 was well tolerated in all dose groups with grade 1-2 anorexia being the most common adverse event. Anorexia was responsive to symptomatic and supportive medications, including prednisone. These data demonstrate that KPT-335 has biologic activity in canine lymphoma, and support continued evaluation of SINE compounds such as KPT-335 in combination with standard chemotherapeutics in canine lymphoma.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 28%
Other 4 10%
Student > Master 3 8%
Student > Doctoral Student 3 8%
Student > Bachelor 2 5%
Other 9 23%
Unknown 8 20%
Readers by discipline Count As %
Veterinary Science and Veterinary Medicine 17 43%
Medicine and Dentistry 5 13%
Biochemistry, Genetics and Molecular Biology 2 5%
Psychology 2 5%
Immunology and Microbiology 1 3%
Other 6 15%
Unknown 7 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2019.
All research outputs
#7,075,393
of 14,091,489 outputs
Outputs from BMC Veterinary Research
#457
of 2,122 outputs
Outputs of similar age
#108,521
of 273,239 outputs
Outputs of similar age from BMC Veterinary Research
#1
of 1 outputs
Altmetric has tracked 14,091,489 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,122 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,239 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them